


PDA Survey



2013 PDA Objectionable Microorganisms for Nonsterile Pharmaceutical, Consumer Health, Medical Devices, Dietary Supplement and Cosmetic Products



Connecting People, Science and Regulation®



www.pda.org/bookstore

The image shows three petri dishes containing agar media with various bacterial growth patterns. The top-right dish shows a confluent growth of small, dark colonies. The bottom-left dish shows a streaked growth pattern with several distinct, elongated colonies. The bottom-right dish shows a confluent growth of small, dark colonies.

PDA Survey
*2013 PDA Objectionable
Microorganisms for
Nonsterile Pharmaceutical,
Consumer Health, Medical
Devices, Dietary Supplement
and Cosmetic Products*

ISBN: 978-0-939459-66-7

© 2014 Parenteral Drug Association, Inc.

All rights reserved.



PDA Objectionable Microorganisms Survey Team Members

Donald English, Avon, (Chair)

Anthony Cundell, Ph.D., Merck

David Roesti, Ph.D., Novartis

Dona Reber, Pfizer

Anil Sawant, Ph.D., Johnson & Johnson

Scott Sutton, Ph.D., Consultant

Acknowledgement

The team would like to recognize John Krowka, Ph.D., Personal Care Products Council, for distributing the survey throughout his network in order to help us broaden the scope of responses beyond pharmaceutical microbiology.

Table of Contents

INTRODUCTION	1
GENERAL DEMOGRAPHICS	2
MICROBIAL TESTING OF NONSTERILE PRODUCT FORMULATIONS	6
PURIFIED WATER SYSTEMS	10
CLEANING AND SANITIZATION OF NONSTERILE MANUFACTURING EQUIPMENT	14
MICROBIAL CONTENT TEST METHODS	15
RAPID MICROBIAL TEST METHODS	21
IDENTIFICATION TEST METHODS OF RECOVERED MICROBIAL ISOLATES	24
MICROBIAL ACCEPTANCE CRITERIA FOR NONSTERILE FINISHED PRODUCT FORMULATIONS	29
TYPES OF MICROORGANISM CONSIDERED AS OBJECTIONABLE IN NONSTERILE PRODUCT FORMULATIONS	31
RISK FACTORS ANALYSIS	34
MICROBIAL TEST SPECIFICATIONS	42
STEPS TAKEN IN PREVENTING THE ISOLATION OF OBJECTIONABLE MICROORGANISMS	46
FEEDBACK FROM SURVEY RESPONDENTS CONCERNING WHICH MICROBIAL SPECIES COULD BE CONSIDERED AS OBJECTIONABLE FOR THEIR COMPANY PRODUCED NONSTERILE FINISHED PRODUCT FORMULATIONS	47